Literature DB >> 8573537

Assessment of 'quality of life' using a daily diary card in a randomised trial of chemotherapy in small-cell lung cancer.

N H Gower1, R M Rudd, M C Ruiz de Elvira, S G Spiro, L E James, P G Harper, R L Souhami.   

Abstract

BACKGROUND: Quality of life (QOL) was assessed using a daily diary-card within a multicentre randomised trial of treatment of small-cell lung cancer. The trial compared a weekly dose-intensive regimen with a 3-weekly conventional treatment in good prognosis patients, that is patients with limited disease or extensive disease with a good performance status (ECOG 0or 1) and alkaline phosphatase of less than one and a half times the upper limit of normal. The trial which has been previously reported detected no difference in response or survival. PATIENTS AND METHODS: Daily diary cards (DDCs) were collected for up to eight months from the first day of chemotherapy in a cohort of 75 patients at one centre. Percentages of scores over a specified level were calculated for each of the eight diary card questions and comparisons were made between treatment arms.
RESULTS: During the period of chemotherapy compliance in completing DDCs was 72.5% in the weekly arm and 77.2% in the 3 weekly. Significantly worse scores were reported with weekly chemotherapy during this period for six of the eight parameters, namely: ;nausea, vomiting, happiness, appetite, general well-being and sleep. Recognised problems of QOL data collection, in particular, compliance, attrition and generalisability are highlighted by this study and are discussed in the paper.
CONCLUSIONS: The QOL measurements indicate that 3 weekly chemotherapy is the preferred treatment. This study demonstrates that QOL measurements may be helpful in choosing between treatment alternatives where no difference in outcome is observed.

Entities:  

Mesh:

Year:  1995        PMID: 8573537     DOI: 10.1093/oxfordjournals.annonc.a059247

Source DB:  PubMed          Journal:  Ann Oncol        ISSN: 0923-7534            Impact factor:   32.976


  7 in total

Review 1.  Management of lung cancer.

Authors:  A Melville; A Eastwood
Journal:  Qual Health Care       Date:  1998-09

Review 2.  Clinical trials in lung cancer: nihilism versus enthusiasm.

Authors:  S G Spiro
Journal:  Thorax       Date:  1997-07       Impact factor: 9.139

3.  A randomised phase IIb trial to assess the efficacy of ReCharge ice cream in preventing chemotherapy-induced diarrhoea.

Authors:  D Perez; K J Sharples; R Broom; M Jeffery; J Proctor; V Hinder; S Pollard; J Edwards; A Simpson; J Scott; S Benge; G Krissansen; A Geursen; K Palmano; A MacGibbon; D Keefe; M Findlay
Journal:  Support Care Cancer       Date:  2015-05-28       Impact factor: 3.603

4.  The health-related quality of life and survival of small-cell lung cancer patients: results of a companion study to CALGB 9033.

Authors:  M J Naughton; J E Herndon; S A Shumaker; A A Miller; A B Kornblith; D Chao; J Holland
Journal:  Qual Life Res       Date:  2002-05       Impact factor: 4.147

5.  How quality of life data contribute to our understanding of cancer patients' experiences? A study of patients with lung cancer.

Authors:  Ali Montazeri; Robert Milroy; David Hole; James McEwen; Charles R Gillis
Journal:  Qual Life Res       Date:  2003-03       Impact factor: 4.147

6.  Measuring quality of life: impact of chemotherapy for advanced colorectal cancer. Experience from two recent large phase III trials.

Authors:  H Anderson; M K Palmer
Journal:  Br J Cancer       Date:  1998       Impact factor: 7.640

7.  Initial prognostic factors in small-cell lung cancer patients predicting quality of life during chemotherapy. Swiss Group for Clinical Cancer Research (SAKK).

Authors:  J Bernhard; C Hürny; M Bacchi; R A Joss; F Cavalli; H J Senn; S Leyvraz; R Stahel; C Ludwig; P Alberto
Journal:  Br J Cancer       Date:  1996-11       Impact factor: 7.640

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.